About Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals is a publicly listed company based in Bermuda founded in 2015. Therapeutics for multiple diseases are developed by Kiniksa Pharmaceuticals. Kiniksa Pharmaceuticals has raised $320 million across 3 funding rounds from investors including Fidelity Investments, ArrowMark Partners and Baker Brothers Plumbing, Air Conditioning & Electrical. The company has 315 employees. Its chief executive, as recorded, is Sanj K Patel. Its website kiniksa.com draws about 11 thousand monthly visits. Kiniksa Pharmaceuticals offers products and services including Immune-Modulating Assets, Disease Registries, and Pipeline Medicines. Its focus areas include Life Sciences, Rare Diseases, Drugs and Autoimmune Diseases. Its legal entity is Kiniksa Pharmaceuticals Corp.
Company details
Kiniksa Pharmaceuticals was founded in 2015 and is headquartered in Bermuda. The company operates in the biopharmaceutical sector, focusing on the development of drug candidates for various diseases. Its pipeline includes Arcalyst (rilonacept) targeted at pericarditis, Mavrilimumab for cardiac conditions, and Abiprubart for autoimmune disorders. Operations emphasize clinical-stage therapeutics to address unmet medical needs across multiple indications.
- Headquarters Bermuda
- Employees 315
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website kiniksa.com
- Social LinkedIn Instagram YouTube
- Legal Name Kiniksa Pharmaceuticals, Ltd.
- Annual Revenue$677.56 M (USD)60.09as on Dec 31, 2025
- Net Profit$59.01 M (USD)as on Dec 31, 2025
- EBITDA$78.78 M (USD)as on Dec 31, 2025
- Total Equity Funding$320M (USD)
in 3 rounds
- Latest Funding Round$200M (USD), Series C
May 2018
- InvestorsFidelity Investments
& 5 more
- Employee Count315
Products & Services of Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals offers a comprehensive portfolio of products and services, including Immune-Modulating Assets, Disease Registries, and Pipeline Medicines.
Develops treatments for critical immune-related diseases
Provides platforms for tracking and managing patient diseases
Advances new therapies for rare and debilitating conditions
Apps and channels of Kiniksa Pharmaceuticals
its YouTube channel Kiniksa has 56 subscribers and 10 videos.
Videos from Kiniksa Pharmaceuticals
The most watched videos on Kiniksa Pharmaceuticals's YouTube channel, Kiniksa (56 subscribers). Click a video to play it here.
More on Kiniksa.
Funding Insights of Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals has successfully raised a total of $320M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $200 million completed in May 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $320M
- Total Rounds 3
- Last Round Series C — $200M
- First Round $80M
(Jun 2015)
- Investors Count 6
All 3 funding rounds of Kiniksa Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2018 | $200M | Series C | – | Sofinnova Investments, Venrock | |
| Jun 2017 | $40M | Series B | – | – | – |
| Jun 2015 | $80M | Series A | – | – | – |
6 investors in total: 6 institutional.
Investors in Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, ArrowMark Partners and Baker Brothers Plumbing, Air Conditioning & Electrical.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Biotech funding, drug development support, and investment in life sciences. | sofinnova.com | |||
Venture capital firm focused on tech sectors | venrock.com | Palo Alto, United States | ||
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States | ||
Provider of brokerage accounts, retirement planning, wealth management, and trading platforms | 1946 | fidelity.com | Boston, United States | |
Diversified asset management services are provided to investors. | 2007 | arrowmarkpartners.com | Denver, United States | |
Plumbing, air conditioning, and electrical services are provided. | 1945 | bakerbrothersplumbing.com | Dallas, United States |
Investor details for Kiniksa Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Kiniksa Pharmaceuticals
166 people are tracked at Kiniksa Pharmaceuticals (84 in leadership, 8 in board & advisors, 74 in team); the tracked headcount is 315.
| Name | Role | Group |
|---|---|---|
Sanj K Patel | CEO | Leadership |
John Paolini | CMO | Leadership |
Tsui-Lin Huang | Senior Director, IT R&d | Leadership |
Cesar Hagopian | Associate Director Of Information Technology | Leadership |
Mark Ragosa | Chief Financial Officer | Leadership |
Sherrell Cook | Director | Leadership |
Jeff Hawk | Regional Sales Director | Leadership |
Todd Fuller | Regional Sales Director | Leadership |
Megan L | Senior Director, Pricing & Contracting Operations | Leadership |
Derek Dorman | Associate Director, Downstream Process Development And Manufacturing | Leadership |
Shaun Grier | Senior Director, Internal Manufacturing And Process Development | Leadership |
Narissa Edwards | Associate Director, Patient Access Lead | Leadership |
Alejandro Reyes | Regional Sales Director | Leadership |
Alexander Baillargeon | Associate Director, Fp&a | Leadership |
Melissa Pletzer | Director, Quality Control | Leadership |
Stephanie Flanders | Associate Director, Marketing Operations | Leadership |
Rebecca Hamilton | Executive Director, Supply Chain | Leadership |
Daisy Dillon | Senior Director, Clinical Operations | Leadership |
Mike Megna | VP Finance & Chief Accounting Officer | Leadership |
Chris Heberlig | CFO | Leadership |
146 more people are available in the full profile.
Complete people profiles for Kiniksa Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol KNSA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date24 May 2018
- Listed onNASDAQ: KNSA
- Listed entityKiniksa Pharmaceuticals, Ltd.
- Exchange sectorHealth technology
- ISINGB00BRXB0C07
- Share price$78.53 (-0.9% on the day) · 2026-10-13
- Market capitalisation$6.13B
- Price to earnings79.8
- EPS (diluted, trailing year)$0.98
- Volume (last session)575,787
Financials of Kiniksa Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $677.6M | $59.0M | $78.8M |
| 2024 | $423.2M | -$43.2M | -$43.9M |
| 2023 | $270.3M | $14.1M | -$23.1M |
| 2022 | $220.2M | $183.4M | $14.0M |
| 2021 | $38.5M | -$157.9M | -$152.6M |
Detailed financial statements for Kiniksa Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Kiniksa Pharmaceuticals
4 dated milestones of Kiniksa Pharmaceuticals across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Kiniksa Pharmaceuticals is founded.
- Funding First funding round of $80.0M.
- Funding Latest funding round, Series C, of $200.0M.
- IPO Lists on the stock exchange (IPO).
Web traffic of Kiniksa Pharmaceuticals
The website of Kiniksa Pharmaceuticals (kiniksa.com) receives about 10.7K visits a month and ranks #2,615,908 among all websites worldwide, #3,577 in Biotechnology and Pharmaceuticals.
- Monthly visits10.7K
▲ 20.6% vs previous month
- Unique visitors4.3K
per month
- Global rank#2,615,908
among all websites
- Category rank#3,577
Health · Biotechnology and Pharmaceuticals
- Bounce rate55%
- Pages per visit1.4
- Average visit14 sec
- DevicesDesktop 33% · Mobile 67%
Websites whose visitors overlap most with Kiniksa Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| hcplive.com | 100% | #212,282 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Kiniksa Pharmaceuticals
Complete news archive for Kiniksa Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals was founded in 2015.
Kiniksa Pharmaceuticals is headquartered in Bermuda.
Sanj K Patel is the CEO of Kiniksa Pharmaceuticals, as recorded in our data.
Kiniksa Pharmaceuticals is a funded company, having raised a total of $320M across 3 funding rounds to date. The company's 1st funding round was a Series A of $80M, raised on Jun 2015.
Kiniksa Pharmaceuticals has 315 employees.
Annual revenue of Kiniksa Pharmaceuticals is $677.56M as on Dec 31, 2025.
Kiniksa Pharmaceuticals was founded in 2015 and is headquartered in Bermuda. The company operates in the biopharmaceutical sector, focusing on the development of drug candidates for various diseases. Its pipeline includes Arcalyst (rilonacept) targeted at pericarditis, Mavrilimumab for cardiac conditions, and Abiprubart for autoimmune disorders. Operations emphasize clinical-stage therapeutics to address unmet medical needs across multiple indications.
Kiniksa Pharmaceuticals offers Immune-Modulating Assets, Disease Registries, and Pipeline Medicines.
Yes, Kiniksa Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol KNSA.
Kiniksa Pharmaceuticals has 6 investors. Key investors include Fidelity Investments, ArrowMark Partners, Baker Brothers Plumbing, Air Conditioning & Electrical, Sofinnova, and Venrock.
Kiniksa Pharmaceuticals operates through Kiniksa Pharmaceuticals Corp..